NYSE •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization506.6 mln
Float19.97 mln
Earnings Date08/06/2026
Beneish M-Score
25.15
Highly suspicious
1-Year Forecast
31.00
Transformational upside
Relative Strength
97
/ 100
Top performer
Debt / Equity
0.03
Debt-free
ROE
-44.95
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Evommune is a Palo Alto-based biotech company focused on treating chronic inflammatory conditions such as hives, eczema, and ulcerative colitis. Its two lead drug candidates, EVO756 and EVO301, are currently in clinical testing and aim to address the root causes of these diseases rather than just their symptoms. Founded in 2020, the company is still in the early stages of bringing its treatments to market.
